Lund, Sweden, 2014-09-22 08:45 CEST (GLOBE NEWSWIRE) -- New BSI-data have been generated using the software package, EXINI boneBSI, for a prostate cancer project. The results will be presented at the medical science conference “European Society for Medical Oncology (ESMO) 2014 Congress” in Madrid, Spain, September 26–30. The project includes EXINI’s biomarker BSI (Bone Scan Index) and a novel drug substance developed for the treatment of prostate cancer.
Prostate cancer spreads to the skeleton, and bone scintigraphy (bone scan) is used for monitoring this progression of the disease. With EXINI’s unique BSI-calculation, clinicians acquire a measurement of the skeletal tumour burden, which has a significant prognostic value. The change in the BSI observed during the treatment of patients suffering from metastatic castration-resistant prostate cancer showed that the BSI acts as a marker of the clinical effects of the drug.
“This study indicates that quantification of bone metastases using the BSI is a valuable complement to traditional methods for the evaluation of treatment response in metastatic prostate cancer.” says Magnus Aurell, CEO, EXINI Diagnostics AB.
More on Bone Scan Index (BSI):
BSI is an imaging biomarker providing fast, accurate and quantifiable information to be used for diagnostics and stratification, monitoring of treatment response and increased prognostic accuracy in the management of patients suffering from skeletal metastases originating from prostate - or breast cancer.
BSI has also demonstrated its importance in the process of developing new drugs, thus proving itself equally important for clinical use as for pharmaceutical industry. EXINI boneBSI serves as the only software capable to extract BSI-value for both these purposes.
www.bonescanindex.org
www.exini.com/software-bone-bsi/
www.esmo.org
For more information, please contact:
Magnus Aurell, CEO
Phone: +46 46 286 54 25
E-mail: magnus.aurell@exini.com
About EXINI Diagnostics AB (publ)
EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as cancer, coronary heart disease, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock market NASDAQ OMX First North and has about 600 shareholders. Principal owner is Bo Håkansson. Consensus acts as Certified Adviser.
________________________________________________________________________
EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden
Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com
